Abstract
Objective: Our aim was to analyze frequency of Irritable-bowel-syndrome (IBS) in migraine and episodic tension type headache (ETTH) patients; frequency of primary headache disorders in IBS patients; presence of polimorphism in serotonin transporter and serotonin receptor-2A gene to explain possible association between IBS and primary headache disorders. Background: Patients with IBS have increased hypothalamic gray matter activity suggesting an association between stress, and hypothalamic-pituitary-adrenal axis. In this perspective IBS can be defined as migraine of the bowels. In IBS patients with constipation serotonin secretion in plasma is being decreased. There is defect in serotonin signaling in IBS and decrease in mucosal serotonin and immune-reactivity of serotonin transporter. Methods: 107 episodic migraine and 53 ETTH patients, 107 patients with IBS and 53 healthy control subjects were enrolled. Migraine and ETTH patients were examined whether they have IBS symptoms and IBS patients were examined for primary headaches. Presence of polimorphism in serotonin transporter and serotonin receptor 2A gene were assessed. Results: IBS frequency in migraine patients was found to be two-fold compared with ETTH (54.2[percnt] vs 28.3[percnt], p<0.05). Unilaterality and photophobia was more pronounced in migraine patients with IBS. Migraine was found in 38 patients (35.5[percnt]) and ETTH was found in 24 patients (22.4[percnt]) with IBS. Comparing with control subjects significant difference in terms of 5-HTT VNTR gene 10/12 genotype was observed in migraine patients (p=0.0247). When patients with ETTH and controls were compared there was significant difference in terms of 5-HTT VNTR 10/12 (p=0.0103) and 12/12 (p=0.0043) genotypes. When patients with IBS and controls were compared there was a significant difference in terms of 5-HT2A - 1438 AA genotype (p=0.0005). Conclusion: Our study suggests a high possibility of phenotypic and genotypic association between the IBS and primary headache disorders and supports the presence of some shared pathophysiological basis.
Disclosure: Dr. Uluduz has nothing to disclose. Dr. Cakmak has nothing to disclose. Dr. Ozge has nothing to disclose. Dr. Ucbilek has nothing to disclose. Dr. Sezgin has nothing to disclose. Dr. Soylemez has nothing to disclose. Dr. Temel has nothing to disclose. Dr. Kanik has nothing to disclose.
Tuesday, April 19 2016, 8:30 am-7:00 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.